These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 24683532)
1. DLC1 suppresses NF-κB activity in prostate cancer cells due to its stabilizing effect on adherens junctions. Tripathi V; Popescu NC; Zimonjic DB Springerplus; 2014; 3():27. PubMed ID: 24683532 [TBL] [Abstract][Full Text] [Related]
2. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion. Tripathi V; Popescu NC; Zimonjic DB Oncogene; 2014 Feb; 33(6):724-33. PubMed ID: 23376848 [TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: prospects for gene therapy. Guan M; Tripathi V; Zhou X; Popescu NC Cancer Gene Ther; 2008 Jun; 15(6):371-81. PubMed ID: 18369381 [TBL] [Abstract][Full Text] [Related]
5. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057 [TBL] [Abstract][Full Text] [Related]
6. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. Wong CC; Wong CM; Ko FC; Chan LK; Ching YP; Yam JW; Ng IO PLoS One; 2008 Jul; 3(7):e2779. PubMed ID: 18648664 [TBL] [Abstract][Full Text] [Related]
7. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation. Ko FC; Ping Yam JW Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040 [TBL] [Abstract][Full Text] [Related]
8. Deleted in liver cancer 1 suppresses the growth of prostate cancer cells through inhibiting Rho-associated protein kinase pathway. Gong H; Chen K; Zhou L; Jin Y; Chen W Asian J Urol; 2023 Jan; 10(1):50-57. PubMed ID: 36721699 [TBL] [Abstract][Full Text] [Related]
9. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. Zhou X; Yang XY; Popescu NC Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346 [TBL] [Abstract][Full Text] [Related]
10. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Healy KD; Hodgson L; Kim TY; Shutes A; Maddileti S; Juliano RL; Hahn KM; Harden TK; Bang YJ; Der CJ Mol Carcinog; 2008 May; 47(5):326-37. PubMed ID: 17932950 [TBL] [Abstract][Full Text] [Related]
11. PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Ko FC; Chan LK; Sze KM; Yeung YS; Tse EY; Lu P; Yu MH; Ng IO; Yam JW Nat Commun; 2013; 4():1618. PubMed ID: 23511482 [TBL] [Abstract][Full Text] [Related]
12. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA. Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702 [TBL] [Abstract][Full Text] [Related]
13. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Yang X; Popescu NC; Zimonjic DB Cancer Res; 2011 Apr; 71(8):2916-25. PubMed ID: 21372205 [TBL] [Abstract][Full Text] [Related]
14. Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression. Sánchez-Martín D; Otsuka A; Kabashima K; Ha T; Wang D; Qian X; Lowy DR; Tosato G J Natl Cancer Inst; 2018 Apr; 110(4):390-399. PubMed ID: 29202196 [TBL] [Abstract][Full Text] [Related]
15. Combination of dihydroartemisinin and resveratrol effectively inhibits cancer cell migration Gao J; Ma F; Wang X; Li G Food Funct; 2020 Nov; 11(11):9573-9584. PubMed ID: 33150340 [TBL] [Abstract][Full Text] [Related]
16. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Kim TY; Jackson S; Xiong Y; Whitsett TG; Lobello JR; Weiss GJ; Tran NL; Bang YJ; Der CJ Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16868-73. PubMed ID: 24082123 [TBL] [Abstract][Full Text] [Related]
17. The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer. Sabbir MG; Prieditis H; Ravinsky E; Mowat MR PLoS One; 2012; 7(7):e40302. PubMed ID: 22792269 [TBL] [Abstract][Full Text] [Related]
18. DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Erlmann P; Schmid S; Horenkamp FA; Geyer M; Pomorski TG; Olayioye MA Mol Biol Cell; 2009 Oct; 20(20):4400-11. PubMed ID: 19710422 [TBL] [Abstract][Full Text] [Related]
19. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Ullmannova-Benson V; Guan M; Zhou X; Tripathi V; Yang XY; Zimonjic DB; Popescu NC Leukemia; 2009 Feb; 23(2):383-90. PubMed ID: 18923442 [TBL] [Abstract][Full Text] [Related]
20. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Yang XY; Guan M; Vigil D; Der CJ; Lowy DR; Popescu NC Oncogene; 2009 Mar; 28(11):1401-9. PubMed ID: 19151751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]